feedback

Course Director

Arjun Balar, MD
Arjun Balar, MD

Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York

Faculty

Joaquim Bellmunt
Joaquim Bellmunt, MD, PhD

Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Petros Grivas
Petros Grivas, MD, PhD

University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

Accredited by

Penn State College of Medicine

Activity Description and Educational Objectives

In this activity, developed in collaboration with the Bladder Cancer Advocacy Network, a panel of leading bladder cancer experts pair important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide decision-making in the clinic. The panel also provides guidance on how to manage several challenging patient types across the disease spectrum—from locally advanced metastatic to non-muscle–invasive bladder cancer.

Upon completion of this activity, participants should be better able to:
  • Review the rationale for the use of and latest evidence on approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, FGFR inhibitors, and gene therapy, throughout the bladder cancer disease continuum
  • Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer
  • Optimally apply new and emerging treatment approaches for the management of bladder cancer while considering the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences
  • Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer
  • Recommend current and ongoing clinical trials that incorporate checkpoint blockade, novel targeted approaches, and gene therapy to eligible patients across disease settings in bladder cancer

Target Audience

This activity has been designed to meet the educational needs of medical and urologic oncologists and other clinicians involved in the management of patients with bladder cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 17, 2020 - March 16, 2021
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair

Arjun Balar, MD
Associate Professor of Medicine
Director – Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York

Arjun Balar, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca/MedImmune; Genentech, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Nektar Therapeutics; Pfizer Inc.; and Seattle Genetics, Inc.
Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc.; Immunomedics; Merck & Co., Inc.; Nektar Therapeutics; and Seattle Genetics, Inc. Research funding to Institution.
Other Financial or Material Support from Nektar Therapeutics for Steering Committee Membership. AstraZeneca/MedImmune; Genentech, Inc.; and Merck & Co., Inc. for speaking engagements.

Faculty

Joaquim Bellmunt, MD, PhD
Director, Bladder Cancer Program
Beth Israel Deaconess Medical Center
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Joaquim Bellmunt, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Genentech; Merck & Co., Inc.; Pfizer; and Pierre Fabre.
Grant/Research Support from Merck Sharp & Dohme; Sanofi; and Takeda.
Royalties, patents from UpToDate.

Petros Grivas, MD, PhD
Associate Professor, Department of Medicine, Division of Oncology
Clinical Director, Genitourinary Cancers Program
University of Washington
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Petros Grivas, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Foundation Medicine, Inc.; Genzyme Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; and Seattle Genetics, Inc.
Grant/Research Support from Bavarian Nordic; Bristol-Myers Squibb; Clovis Oncology; Debiopharm Group; Immunomedics; and Pfizer, Inc.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME/MOC credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6592-20-T.

MOC Statement

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Providership


This CME/MOC activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Astellas and Seattle Genetics, FerGene Inc., Janssen Biotech, Inc., and Merck & Co., Inc.

This CME/MOC activity has been developed in collaboration with the Bladder Cancer Advocacy Network.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.